Caplin Point Laboratories — 360° view

Caplin Point Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹630 crore and net profit of ₹182 crore for the September 2026 quarter.

Caplin Point Laboratories (NSE: CAPLIPOINT) closed at ₹2,029.10 on 20 Nov 2026, up 5.7% over the past year. Its market capitalisation is ₹15,424 crore and it trades at 22.4 times earnings.

Share price
₹2,029.10 (20 Nov 2026)
Market cap
₹15,424 Cr (20 Nov 2026)
P/E
22.38 (20 Nov 2026)
Revenue
₹630 Cr (September 2026 quarter)
Net profit
₹182 Cr (September 2026 quarter)
ROCE
24.2% (FY26)
ROE
20.9% (FY26)
Book value
₹513 (FY26)
Dividend yield
0.39% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,990.00 / ₹1,500.30 (20 Nov 2026)
1-year return
5.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: CAPLIPOINT

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.